Answers are grounded in this paper and cite their sources.
Enantioselective synthesis achieves >99% ee in scaffold for drug discovery, suggesting new pathways in medicinal chemistry.
An enantioselective synthesis (>99% ee) of (-)-(1R,2S,3R,4R,Z)-7-(bromomethylene)-N-(4-fluoro-3-(trifluoromethyl)phenyl)-3-(2,2,2-trifluoroacetamido)bicyclo[2.2.1]heptane-2-carboxamide ((-)-1), a scaffold for divergent drug discovery synthesis, has been developed. The synthesis employed dimethyl(phenyl)silyl moiety as a "masked" hydroxy group and started with an exclusively endo selective Diels-Alder reaction of readily available cyclopenta-2,4-dien-1-yldimethyl(phenyl)silane (8) with maleic anhydride (3) to afford the tricyclic anhydride 17. Desymmetrization of this meso-anhydride 17 was enabled by a high yielding quinidine-mediated opening with benzyl alcohol to generate the benzyl hemiester 4 with >93% ee which was upgraded to greater than 99% ee by chiral resolution with (1R,2R)-(-)-1,2-diaminocyclohexane 19. Other key features of this synthetic route involved a Curtius rearrangement for the formation Teoc-protected amino bicyclo[2.2.1]heptane intermediate 23, a Fleming-Tamao oxidation for the conversion of dimethyl(phenyl)silyl to the hydroxy group and a Swern oxidation of the alcohol 30 to the strained-ring ketone 31. Finally, the bromo olefin of (-)-1 was installed by a stereoselective Wittig reaction of 31 using (bromomethyl)triphenylphosphonium bromide.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: